ViferaXS Raises €12 Million to Advance Phase II Trial in Chronic Lymphocytic Leukemia and Expand Its Oncology Pipeline
Why now
Thesis: Small private CLL financing, immaterial to public markets
Catalyst to watch: Phase II trial data readout
Main risk: Early-stage trial failure risk
Why it matters
Early-stage oncology financing is routine; private round with no listed comparables moves no public assets.
Details
Financing round of €12 million closed, including grant funding, led by SPRIND (the German Federal Agency for Breakthrough Innovation) and Huma, with participation from private investors Proceeds fund a Phase II trial of CLLTAXS01 in chronic lymphocytic leukemia (CLL), plus upcoming Phase...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-23 12:15 UTC